Loading cancer entity…
Loading cancer entity…
Clinical trials
6,746 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,045)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06249854 | Efficacy and Safety of Combination Therapy With Bojungikki-tang and Pembrolizumab Monotherapy in Patients With Advanced Non-small Cell Lung Cancer | completed | Phase 2 | 26 | Korea Institute of Oriental MedicineOTHER_GOV | 1 | Aug 5, 2026 | clinicaltrials |
| NCT04640259 | Epidemiology of Young Lung Cancer - Survey(EoYLC) | completed | — | 187 | Addario Lung Cancer Medical InstituteOTHER | 1 | Aug 4, 2026 |
| clinicaltrials |
| NCT06448793 | Patient and Physician Preference Study in Resectable, Non-small Cell Lung Cancer Treatments | completed | — | 650 | Bristol-Myers SquibbINDUSTRY | 1 | Aug 4, 2026 | clinicaltrials |
| NCT06139419 | The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC | completed | Phase 2 | 114 | Sun Yat-sen UniversityOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT06532032 | A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer(swalloWTail) | completed | Phase 1 / Phase 2 | 12 | Janssen Research & Development, LLCINDUSTRY | 4 | Jul 31, 2026 | clinicaltrials |
| NCT02718066 | Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 96 | HUYABIO International, LLC.INDUSTRY | 1 | Jul 30, 2026 | clinicaltrials |
| NCT05258279 | Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR Mutations | completed | Phase 2 | 30 | Juntendo UniversityOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT03581487 | Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT04563871 | Efficacy and Safety of 80mg Osimertinib in Patients With Non-small Cell Lung Cancer(NSCLC)(BLOSSOM) | completed | Phase 2 | 73 | Sehhoon ParkOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT04158440 | Phase III Study of Toripalimab Versus Placebo Plus Chemotherapy in Resectable NSCLC | completed | Phase 3 | 501 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT04776447 | Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO)(APOLO) | completed | Phase 2 | 38 | Fundación GECPOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT04702009 | Efficacy and Safety of First-line Anti-PD-1/PD-L1 Monoclonal Antibody in Combination With Chemotherapy and Bronchoscopy-assisted Interventional Therapy in Patients With Advanced Central Non-small Cell Lung Cancer | completed | Phase 2 / Phase 3 | 33 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT06477055 | The Recurrence Gene Profiles of Adjuvant Osimertinib Therapy in Resected Non-Small-Cell Lung Cancer(RAISE) | completed | — | 43 | Hunan Province Tumor HospitalOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT07192926 | Body Composition and Blood-Based Prognostic Markers in Immunotherapy-Treated Metastatic Non-Small Cell Lung Cancer(SARC-CTI) | completed | — | 155 | Ankara Etlik City HospitalOTHER_GOV | 1 | Jul 21, 2026 | clinicaltrials |
| NCT04919369 | All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer | completed | Phase 1 | 18 | Dwight OwenOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT05775289 | A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer | completed | Phase 2 | 182 | Hoffmann-La RocheINDUSTRY | 11 | Jul 20, 2026 | clinicaltrials |
| NCT03383302 | SBRT With Immunotherapy in Early Stage Non-small Cell Lung Cancer: Tolerability and Lung Effects(STILE) | completed | Phase 1 / Phase 2 | 36 | Royal Marsden NHS Foundation TrustOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT04592523 | A Study of Usage of Brigatinib in the Treatment of Adult Participants for Approved Indications In South Korea | completed | — | 271 | TakedaINDUSTRY | 1 | Jul 16, 2026 | clinicaltrials |
| NCT04374877 | Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors | completed | Phase 1 | 145 | Coherus Oncology, Inc.INDUSTRY | 3 | Jul 15, 2026 | clinicaltrials |
| NCT07068139 | AI-Based Prediction of Stage and Survival in Non-Small Cell Lung Cancer: A Retrospective Study | completed | — | 156 | Hilkat Fatih ElverdiOTHER | 0 | Jul 15, 2026 | clinicaltrials |
| NCT01964157 | An Open-label, Multicenter, Phase II Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement | completed | Phase 2 | 32 | Yonsei UniversityOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT03519971 | Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer | completed | Phase 3 | 328 | AstraZenecaINDUSTRY | 14 | Jul 14, 2026 | clinicaltrials |
| NCT02186847 | Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer | completed | Phase 2 | 170 | NRG OncologyOTHER | 3 | Jul 13, 2026 | clinicaltrials |
| NCT06678555 | A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer (NSCLC) Which Has Spread Out. | completed | — | 22 | PfizerINDUSTRY | 1 | Jul 10, 2026 | clinicaltrials |
| NCT02009449 | A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors(IVY) | completed | Phase 1 | 353 | Eli Lilly and CompanyINDUSTRY | 1 | Jul 9, 2026 | clinicaltrials |
| NCT04905316 | A Study of Canakinumab With Chemotherapy, Radiation Therapy, and Durvalumab in People With Lung Cancer(CHORUS) | completed | Phase 2 | 41 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT06403436 | A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors(TT-CSP-001) | completed | Phase 1 | 45 | TOLREMO therapeutics AGINDUSTRY | 3 | Jul 7, 2026 | clinicaltrials |
| NCT02843568 | Improving Pulmonary Function Following Radiation Therapy | completed | N/A | 122 | University of Wisconsin, MadisonOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT04609566 | Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors | completed | Phase 2 | 161 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 1 | Jul 6, 2026 | clinicaltrials |
| NCT03603002 | Pathologic and Immunologic Response After Ablative Radiation in Lung Cancer | completed | N/A | 6 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT05375994 | Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients(RAMP204) | completed | Phase 1 / Phase 2 | 12 | Verastem, Inc.INDUSTRY | 1 | Jul 2, 2026 | clinicaltrials |
| NCT07682012 | LungVision AI-Augmented Fluoroscopic Navigation for Intraoperative Pulmonary Nodule Localization | completed | N/A | 14 | Tri-Service General Hospital (TSGH)OTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT02911259 | Suction on Post-Operative Chest Tubes(SPOCT) | completed | N/A | 230 | Rigshospitalet, DenmarkOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT03801304 | Trial to Evaluate Safety and Efficacy of Vinorelbine With Metronomic Administration in Combination With Atezolizumab as Second-line Treatment for Patients With Stage IV Non-small Cell Lung Cancer(VinMetAtezo) | completed | Phase 2 | 80 | University Hospital, BrestOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT04248829 | Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301) | completed | Phase 3 | 393 | Yuhan CorporationINDUSTRY | 13 | Jun 29, 2026 | clinicaltrials |
| NCT04566432 | Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated NSCLC Patients | completed | — | 252 | Geneplus-Beijing Co. Ltd.INDUSTRY | 1 | Jun 29, 2026 | clinicaltrials |
| NCT04939324 | Molecular Profiling of Exosomes in Tumor-draining Vein of Early-staged Lung Cancer(ExOnSite-Pro) | completed | N/A | 30 | University Hospital, LimogesOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT02206334 | Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Breast Cancer, Non-small Cell Lung Cancer, or Prostate Cancer | completed | Phase 1 | 42 | NRG OncologyOTHER | 3 | Jun 25, 2026 | clinicaltrials |
| NCT02220894 | Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042) | completed | Phase 3 | 1,274 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 25, 2026 | clinicaltrials |
| NCT03088540 | Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 3 | 712 | Regeneron PharmaceuticalsINDUSTRY | 24 | Jun 25, 2026 | clinicaltrials |
| NCT01642251 | Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 156 | National Cancer Institute (NCI)NIH | 1 | Jun 24, 2026 | clinicaltrials |
| NCT05372081 | Clinical and Molecular Study With Digital Support of Patients With Inoperable Lung Cancer(SNF-CLIMEDIN) | completed | — | 200 | Hellenic Cooperative Oncology GroupOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT00324805 | Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery | completed | Phase 3 | 1,501 | National Cancer Institute (NCI)NIH | 5 | Jun 23, 2026 | clinicaltrials |
| NCT00693992 | Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy | completed | Phase 3 | 210 | National Cancer Institute (NCI)NIH | 1 | Jun 23, 2026 | clinicaltrials |
| NCT04084717 | Study of Crizotinib for ROS1 and MET Activated Lung Cancer | completed | Phase 2 | 33 | University Health Network, TorontoOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT04318938 | Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping | completed | Phase 2 | 118 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT05165160 | Residual Disease Evaluation of Resected NSCLC by cirDNA Analysis(LUNGDOC) | completed | N/A | 133 | University Hospital, MontpellierOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT04475939 | Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-Small Cell Lung Cancer(ZEAL-1L) | completed | Phase 3 | 666 | GlaxoSmithKlineINDUSTRY | 27 | Jun 18, 2026 | clinicaltrials |
| NCT04623775 | A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 468 | Bristol-Myers SquibbINDUSTRY | 19 | Jun 18, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Aug 5, 2026source: clinicaltrials